Fujian Shengdi Pharmaceutical Co., Ltd.

This early-stage trial studies an injectable drug called HRS9531 in Chinese adolescents aged 12 to 17 who have obesity. The main goal is to see if the drug is safe and how it moves through the body. Participants will receive either the drug or a placebo, and researchers will trac…

This study tests an injectable drug called HRS9531 in about 9,200 people with atherosclerotic cardiovascular disease (hardened arteries). The goal is to see if it can prevent major heart problems like heart attacks and strokes. Participants will receive either the drug or a place…

This study tests whether HRS9531 tablets can safely lower blood sugar in adults with type 2 diabetes who haven't been helped enough by diet, exercise, or metformin alone. About 240 participants will receive either the drug or a placebo for 20 weeks. The main goal is to see if HRS…

This early-stage study looks at how the body processes HRS9531, a drug for diabetes and weight loss, in people with mild or moderate liver issues compared to those with healthy livers. About 24 adults will receive a single dose to measure drug levels and check for side effects. T…